2 1 Shi Ji Jing Ji Bao Dao·2025-12-16 02:31Core Insights - On December 15, 2023, brokerage firms provided target prices for listed companies, with notable increases for Zejing Pharmaceutical, Zoli Pharmaceutical, and Genesis, showing target price increases of 35.00%, 34.58%, and 27.40% respectively, across the chemical pharmaceuticals, traditional Chinese medicine, and automation equipment industries [1][2]. Group 1: Target Price Increases - Zejing Pharmaceutical received a target price increase of 35.00%, with a latest closing price of 135.00 yuan [2]. - Zoli Pharmaceutical's target price increased by 34.58%, with a closing price of 17.18 yuan [2]. - Genesis saw a target price increase of 27.40%, with a closing price of 11.30 yuan [2]. Group 2: Brokerage Recommendations - A total of 21 listed companies received brokerage recommendations on December 15, with Zoli Pharmaceutical receiving the highest number of recommendations at 5 [3]. - Other companies like Tiandi Technology and Changbao Co. received 1 recommendation each [3]. Group 3: First Coverage Ratings - On December 15, 7 companies received initial coverage from brokerages, including Changbao Co. with an "Accumulate" rating from China Merchants Securities [4]. - Genesis received a "Outperform Industry" rating from China International Capital Corporation [4]. - SAIC Motor was rated "Buy" by Aijian Securities [4].